Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
467.55
+9.24 (+2.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Planned CEO Leadership Transition
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
October 14, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyzing Alnylam Pharmaceuticals's Unusual Options Activity
August 10, 2021
On Tuesday, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
October 27, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Growth Stocks Near 52-Week Highs to Buy Anyway
October 14, 2021
These top performers have what it takes to keep providing outsized gains for patient investors.
Via
The Motley Fool
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
October 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
October 12, 2021
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
10 Health Care Stocks With Unusual Options Alerts In Today's Session
October 08, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option...
Via
Benzinga
Analyst Ratings For Alnylam Pharmaceuticals
October 04, 2021
Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
September 29, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
September 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
September 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
September 07, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
September 01, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
This Robot-Run Large Cap ETF Has Less Apple, Microsoft, Amazon, Facebook Compared To SPY And Is Bullish On These Manufacturing Stocks Instead
August 18, 2021
The Qraft AI-Enhanced US Large Cap ETF (NYSE:QRFT) has revea...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Stocks That Hit 52-Week Highs On Tuesday
August 10, 2021
Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs. Things to Consider: The largest company by market cap to break to a new 52-week high was Pfizer (...
Via
Benzinga
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
August 09, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
August 06, 2021
A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.
Via
The Motley Fool
Why Is Dicerna Stock Getting Slammed Today?
August 06, 2021
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
August 04, 2021
Upgrades For Meritage Homes Corp (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript
August 03, 2021
ALNY earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
August 03, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope
July 30, 2021
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and PeptiDream Inc have announced a license and collaboration agreement to discover and develop peptide-siRNA...
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.